MSI

MSI
Name	Microsatellite instability
Caption	Microsatellite instability schematic
Field	Oncology, Genetics, Pathology
Known for	Biomarker for mismatch repair deficiency and immunotherapy response

MSI

Microsatellite instability is a genetic phenomenon characterized by alterations in short tandem repeat loci across the genome. It is a hallmark of mismatch repair deficiency and has major implications for Lynch syndrome, Colorectal cancer, Endometrial cancer, and precision oncology paradigms. MSI influences prognosis, guides diagnostic algorithms, and informs therapeutic decisions in oncology practice.

Overview

Microsatellite instability arises when defects in DNA mismatch repair components such as MLH1, MSH2, MSH6, and PMS2 allow frameshift mutations in repetitive sequences; this contrasts with genomic instability driven by BRCA1/BRCA2-related homologous recombination deficiency or chromosomal instability seen in TP53-mutant tumors. MSI-high status is detected by panels like the Bethesda guidelines marker set and is often assessed alongside immunohistochemistry for mismatch repair proteins and by next-generation sequencing platforms developed by companies such as Illumina and Thermo Fisher Scientific. Clinical workflows integrate MSI testing with algorithms from organizations including the National Comprehensive Cancer Network and the European Society for Medical Oncology.

Causes and Mechanisms

MSI results from inherited or acquired defects involving proteins encoded by MLH1, MSH2, MSH6, and PMS2, with germline mutations in these genes causing Lynch syndrome and somatic events such as promoter hypermethylation of MLH1 producing sporadic MSI. Defective mismatch repair leads to insertion-deletion mutations at microsatellite loci like those in the TGFBR2 and ACVR2A genes, generating neoantigens recognized by immune effectors including CD8+ T cells and modulated by checkpoints such as PD-1/PD-L1 signaling. MSI interacts with pathways involving WNT signaling (e.g., APC alterations), KRAS and BRAF mutations—most notably the BRAF V600E substitution associated with MLH1 hypermethylation in colorectal neoplasia—and with epigenetic modifications mediated by enzymes like DNMT1.

Clinical Significance and Diagnostics

MSI status serves as a predictive and prognostic biomarker in tumors evaluated by centers such as Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center. Testing modalities include PCR-based panels exemplified by the Bethesda guidelines loci, immunohistochemistry for MLH1, MSH2, MSH6, PMS2, and comprehensive genomic profiling using platforms from Foundation Medicine or assays referenced by College of American Pathologists. MSI-high tumors commonly show high tumor mutational burden, dense infiltration by immune cells evidenced by markers like CTLA-4 and PD-1, and histopathologic features noted in reports from World Health Organization tumor classifications. Detection of MSI prompts cascade testing for Lynch syndrome with confirmation by germline sequencing in reference laboratories certified by American College of Medical Genetics and Genomics.

MSI in Cancer Types

MSI-high prevalence is highest in Endometrial cancer, Colorectal cancer, and subsets of Gastric cancer, with variable occurrence in Ovarian cancer (particularly endometrioid subtype), Small bowel adenocarcinoma, and Hepatocellular carcinoma rarely. MSI characterizes a molecular subset identified in large consortia like The Cancer Genome Atlas and influences classification schemes in guidelines from European Society for Medical Oncology and National Comprehensive Cancer Network. MSI is less frequent in Pancreatic ductal adenocarcinoma and Non-small cell lung carcinoma but, when present, may confer sensitivity to immune checkpoint blockade tested in trials run by groups such as KEYNOTE and CheckMate programs sponsored by companies like Merck and Bristol Myers Squibb.

Therapeutic Implications and Targeted Treatments

MSI-high tumors demonstrate responsiveness to immune checkpoint inhibitors including agents targeting PD-1 such as pembrolizumab and nivolumab, and combinations with anti-CTLA-4 antibodies like ipilimumab have shown activity in clinical trials coordinated by cooperative groups including SWOG and ECOG-ACRIN. Regulatory decisions by agencies such as the U.S. Food and Drug Administration have granted tumor-agnostic approvals based on MSI or mismatch repair deficiency. MSI status can stratify patients for adjuvant chemotherapy decisions in stage II colorectal cancer per guidelines from National Comprehensive Cancer Network and influence eligibility for targeted agents investigated in trials at institutions like Dana-Farber Cancer Institute and Royal Marsden Hospital.

Research and Biomarker Development

Ongoing research integrates MSI assessment with circulating tumor DNA assays developed by startups and companies such as Guardant Health and Grail, and with multi-omic efforts from initiatives like Cancer Moonshot and ICGC. Biomarker research explores combinations of MSI with tumor mutational burden, neoantigen load, and immune gene-expression signatures characterized using platforms by NanoString Technologies and Agilent Technologies. Investigations into resistance mechanisms involve studies of immune escape via mutations in B2M and alterations affecting JAK1/JAK2 signaling, reported in translational programs at Broad Institute and the Wellcome Sanger Institute. Future directions include integrating MSI with artificial intelligence tools from collaborations involving Google Health and IBM Watson Health to refine diagnostics and personalize immunotherapy.

Category:Genetics Category:Oncology Category:Biomarkers